Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement

University of Michigan

Status and phase: Terminated; Phase 4

Conditions: Femoroacetabular Impingement

Treatments: Drug: platelet-rich plasma injection; Drug: Kenalog 10 MG/ML Injectable Suspension

Study type: Interventional

Funder types: Other

Identifiers

NCT02920177

HUM00104340

Details and patient eligibility

About

The purpose of this study is to compare the clinical response of intra-articular platelet rich plasma (PRP) versus corticosteroid injection in patients affected by femoroacetabular impingement (FAI).

Full description

This study will determine if PRP treatment of FAI improves (i) patient reported outcome scores and (ii) hip functional stability compared to standard corticosteroid treatment and if PRP treatment of FAI reduces (i) radiographic and (ii) biochemical markers of joint inflammation and cartilage degradation.

Enrollment: 4 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with symptomatic FAI
• Clinical and radiographic evidence of FAI
• Patients able to provide consent to study participation
• Completion of 6 weeks of physical therapy program

Exclusion criteria

• Established Osteoarthritis (Kellgren-Lawrence > 3)
• Minimum joint space > 2 mm as measured on AP radiograph
• Hip dysplasia (center edge angle < 20° on AP radiograph)
• Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes
• Patients with ongoing infection including HIV and Hepatitis
• Patient with history of osteomyelitis/septic arthritis
• Anticoagulation therapy
• Patients who are pregnant or breast feeding
• Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis
• Patients taking immunosuppressant medication
• Patients with abnormal hematology or serum chemistry lab results
• Patients receiving injection to treatment knee within 2 months of study enrollment
• BMI greater than 35 or less than 20

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

4 participants in 2 patient groups

platelet-rich plasma

Experimental group

Description:

platelet-rich plasma injection into the head-neck junction of the hip joint

Treatment:

Drug: platelet-rich plasma injection

Kenalog 10 mg/mL Injectable Suspension

Active Comparator group

Description:

corticosteroid injection into the head-neck junction of the hip joint

Treatment:

Drug: Kenalog 10 MG/ML Injectable Suspension